How effective is Capmatinib?

Capmatinib (Capmatinib) is a targeted therapy drug, mainly used to treat MET primary tyrosine kinase overexpression (METex14skipping mutations or METincreased) advanced or metastatic non-small cell lung cancer (NSCLC). It is a drug that targets specific genetic mutations and therefore shows certain efficacy in applicable patient groups.

Efficacy evaluation: The efficacy of capmatinib is mainly evaluated through clinical trials. Clinical trials usually conduct long-term follow-up of patients to evaluate the drug's response to tumors, disease control rate, survival prolongation and other indicators to determine the efficacy of the drug. Based on the results of clinical trials, capmatinib is approved for the treatment of patients with certain types of non-small cell lung cancer.

Effectiveness: Capmatinib has shown certain efficacy in applicableNSCLC patients. The specific performance is:

Tumor response: In patients with METex14skipping mutations or METproliferating NSCLC, capmatinib can inhibit the growth and proliferation of tumor cells, make tumors remit or stabilize, thereby delaying the progression of the disease.

Prolonged survival: Some clinical trials have shown that the use of capmatinib can prolong the survival of patients, allowing patients to survive longer.

Disease control rate: The use of capmatinib can improve the disease control rate, even in patients with advanced disease, and can inhibit the development of the disease to a certain extent.

It should be noted that therapeutic effects vary depending on individual differences and tumor characteristics. Different patients may respond differently to capmatinib. Some patients may show a better response to the drug, while others may show a weaker response. Therefore, when using capmatinib, doctors will conduct individualized treatment according to the patient's specific conditions to achieve the best therapeutic effect.

At the same time, it should be noted that although capmatinib is applicableNSCLCIt has shown certain efficacy in patients, but not all patients are suitable for use of this drug. Relevant genetic testing is required before treatment to determine whether the patient has METex14 skipping mutations or MET increases, and whether the patient is suitable for capmatinib treatment. During the treatment process, patients and doctors should closely monitor the efficacy and adverse reactions and adjust the treatment plan in a timely manner to ensure the best efficacy and safety of the drug.

In general, capmatinib, as a targeted therapy for specific gene mutations, has shown certain efficacy in patients with applicable METex14skipping mutations or METproliferative NSCLC, delaying the progression of the disease and improving the patient's survival rate. However, each patient's condition is unique and the response to the drug varies from person to person. Therefore, before using capmatinib, you should understand the patient's specific condition in detail and follow the doctor's recommendations for treatment.

Capmatinib is not currently on the market in China, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug from Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.